BetaEntity Annotation Prototype
← Back to diseases

Annotated abstract

O-070 Update on the saccular endovascular aneurysm lattice system interventional pivotal trial (SEAL™ IT)

neurintsurg · 2026-07-19 · canonical JSON source

3 visible annotations · policy: published · automated confidence ≥ 75.00%

Document resource

Introduction Preclinical animal experiments and initial feasibility studies in humans have shown encouraging outcomes using the novel Saccular Endovascular Aneurysm Lattice (SEAL™) system for the treatment of both ruptured and unruptured wide-neck intracranial aneurysms (IAs). The SEAL™ Interventional Pivotal IDE PMA Trial (SEAL™ IT) is designed to assess the safety and efficacy of the SEAL™ in patients with saccular IAs. This ongoing, prospective, multicenter trial includes three study arms and will enroll a total of 279 participants with wide-neck bifurcation (WNBA), sidewall (SW), or acutely ruptured IAs across 50 U.S. sites.Methods Eligibility requirements include patients aged 20-80 years with a wide-neck saccular intracranial aneurysm (2-19 mm) deemed suitable for treatment with the SEAL™ Intrasaccular Device (SID). Participants receive treatment using the SEAL™ device (Galaxy Therapeutics Inc.) and are monitored at discharge, and again at 3, 6, and 12 months, followed by yearly assessments for up to 5 years. The primary efficacy outcome is defined as complete aneurysm occlusion at 12 months without evidence of parent vessel stenosis or the need for retreatment, as determined by an independent core laboratory. Key safety outcomes include neurological death within 12 months, stroke occurring within the first 30 days, and ipsilateral stroke between 30 days and 1 year.Results As of submission, 163 WNBA, 59 WNSW, and 58 ruptured for a total of 280 patients (76.0% female; mean age 61.6 ± 11.3) have been enrolled at 50 sites. Mean aneurysm width was 5.5 ± 2.3, neck size of 3.9 ± 1.5, and neck-to-dome ratio of 1.5 ± 0.33. SEAL Arc was used in 64.8% and SEAL Base in 35.2%. Technical device success rate is 99.4% for WNBA, 96.6% WNSW, and 98.2% ruptured. The interim complete occlusion rate for the primary group is 71.6% at most recent date based on available imaging.Disclosures D. Altschul: None. B. Jankowitz: None. X. Xin: None. S. Dandapat: None. E. Afreen: None. T. Kass-Hout: None. V. Bansal: None. H. Cuellar-Saenz: None. N. Swamy: None. V. Srinivasan: None. P. Khandelwal: None. P. Bhuva: None. N. Janjua: None. J. Eliyas: None. K. Ebersole: None. R. Priest: None. I. Abecassis: None. F. Almufti: None. E. Pereira: None. A. Badruddin: None. K. Woodward: None. T. Wolfe: None. M. Oliver: None.